Literature DB >> 15089808

Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Romuald Bellmann1, Gerald Kuchling, Pejman Dehghanyar, Markus Zeitlinger, Erich Minar, Bernhard X Mayer, Markus Müller, Christian Joukhadar.   

Abstract

AIMS: The present study addressed the ability of levofloxacin to penetrate into subcutaneous adipose tissues in patients with soft tissue infection.
METHODS: Tissue concentrations of levofloxacin in inflamed and healthy subcutaneous adipose tissue were measured in six patients by microdialysis after administration of a single intravenous dose of 500 mg. Levofloxacin was assayed by high-performance liquid chromatography.
RESULTS: The mean concentration vs time profile of free levofloxacin in plasma was identical to that in inflamed and healthy tissues. The ratios of the mean area under the free levofloxacin concentration vs time curve from 0 to 10 h (AUC(0,10 h)) in tissue to that in plasma were 1.2 +/- 1.0 for inflamed and 1.1 +/- 0.6 for healthy subcutaneous adipose tissue (mean +/- SD). The mean difference in the ratio of the AUC(tissue) : AUC(plasma) for inflamed and healthy tissue was 0.09 (95% confidence interval -0.58, 0.759, P > 0.05). Interindividual variability in tissue penetration was high, as indicated by a coefficient of variation of approximately 82% for AUC(tissue) : AUC(plasma) ratios.
CONCLUSIONS: The penetration of levofloxacin into tissue appears to be unaffected by local inflammation. Our plasma and tissue data suggest that an intravenous dose of 500 mg levofloxacin provides effective antibacterial concentrations at the target site. However, in treatment resistant patients, tissue concentrations may be sub-therapeutic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15089808      PMCID: PMC1884508          DOI: 10.1111/j.1365-2125.2004.02059.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.

Authors:  A T Chow; A Chen; H Lattime; N Morgan; F Wong; C Fowler; R R Williams
Journal:  J Clin Pharm Ther       Date:  2002-04       Impact factor: 2.512

Review 2.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease.

Authors:  C Joukhadar; N Klein; M Frossard; E Minar; H Stass; E Lackner; M Herrmann; E Riedmüller; M Müller
Journal:  Clin Pharmacol Ther       Date:  2001-12       Impact factor: 6.875

Review 4.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  Microdialysis. A novel tool for clinical studies of anti-infective agents.

Authors:  C Joukhadar; H Derendorf; M Müller
Journal:  Eur J Clin Pharmacol       Date:  2001-06       Impact factor: 2.953

6.  Surgery and intensive care procedures affect the target site distribution of piperacillin.

Authors:  M Brunner; T Pernerstorfer; B X Mayer; H G Eichler; M Müller
Journal:  Crit Care Med       Date:  2000-06       Impact factor: 7.598

7.  Target site penetration of fosfomycin in critically ill patients.

Authors:  Christian Joukhadar; Nikolas Klein; Peter Dittrich; Markus Zeitlinger; Alexander Geppert; Keso Skhirtladze; Martin Frossard; Gottfried Heinz; Markus Müller
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

8.  Tissue distribution of imipenem in critically ill patients.

Authors:  Irmgard Tegeder; Achim Schmidtko; Lutz Bräutigam; Andreas Kirschbaum; Gerd Geisslinger; Jörn Lötsch
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

9.  Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.

Authors:  Christian Joukhadar; Nikolas Klein; Bernhard X Mayer; Nicole Kreischitz; Georg Delle-Karth; Peter Palkovits; Gottfried Heinz; Markus Müller
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

10.  Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome.

Authors:  F J Legat; A Maier; P Dittrich; P Zenahlik; T Kern; S Nuhsbaumer; M Frossard; W Salmhofer; H Kerl; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more
  10 in total

Review 1.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling.

Authors:  Andrea N Edginton; Gertrud Ahr; Stefan Willmann; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 4.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 5.  Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.

Authors:  Jaishri Blakeley; Jana Portnow
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10-23       Impact factor: 4.481

6.  Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state.

Authors:  Sandrine Marchand; Denis Frasca; Claire Dahyot-Fizelier; Céline Breheret; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections.

Authors:  J Majcher-Peszynska; G Haase; M Sass; R Mundkowski; A Pietsch; S Klammt; W Schareck; B Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2008-07-25       Impact factor: 2.953

8.  Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens.

Authors:  Zoe Oesterreicher; Iris Minichmayr; Robert Sauermann; Daniela Marhofer; Edith Lackner; Walter Jäger; Alexandra Maier-Salamon; Richard Schwameis; Charlotte Kloft; Markus Zeitlinger
Journal:  Eur J Clin Pharmacol       Date:  2017-09-17       Impact factor: 2.953

9.  Formulation and evaluation of simvastatin polymeric nanoparticles loaded in hydrogel for optimum wound healing purpose.

Authors:  Usama Farghaly Aly; Heba A Abou-Taleb; Ahmed Ah Abdellatif; Nahla Sameh Tolba
Journal:  Drug Des Devel Ther       Date:  2019-05-10       Impact factor: 4.162

10.  Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin.

Authors:  David Busse; André Schaeftlein; Alexander Solms; Luis Ilia; Robin Michelet; Markus Zeitlinger; Wilhelm Huisinga; Charlotte Kloft
Journal:  Pharm Res       Date:  2021-03-15       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.